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The coactivator PGC-1 mediates key responses of skeletal muscle to motor nerve activity. We show here
that neuregulin-stimulated phosphorylation of PGC-1 and GA-binding protein (GABP) allows recruitment
of PGC-1 to the GABP complex and enhances transcription of a broad neuromuscular junction gene program.
Since a subset of genes controlled by PGC-1 and GABP is dysregulated in Duchenne muscular dystrophy
(DMD), we examined the effects of transgenic PGC-1 in muscle of mdx mice. These animals show
improvement in parameters characteristic of DMD, including muscle histology, running performance, and
plasma creatine kinase levels. Thus, control of PGC-1 levels in skeletal muscle could represent a novel
avenue to prevent or treat DMD.
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Peroxisome proliferator-activated receptor  coactivator
1 (PGC-1) is a transcriptional coactivator of nuclear
receptors and other transcription factors that regulates
adaptive mitochondrial function in several other tissues
including heart, brain, liver, and skeletal muscle (for re-
view, see Handschin and Spiegelman 2006). In addition
to the induction of mitochondrial biogenesis per se,
PGC-1 often controls biological programs linked to the
more oxidative state for a particular tissue. The PGC-1
coactivators appear to play a particularly important role
in the biology of skeletal muscle. PGC-1 induces mito-
chondrial biogenesis when expressed in cultured muscle
cells (Wu et al. 1999) and PGC-1 is expressed at highest
levels in muscle beds rich in the oxidative type I and type
IIa muscle fibers, such as soleus (Lin et al. 2002b). Fur-
thermore, PGC-1 expression is induced in most muscle
beds by exercise, both chronic and acute, in rodents and
humans (e.g., Russell et al. 2003). PGC-1 is a key me-
diator of the effects of motor nerve on skeletal muscle,
suggesting the possibility that it might mediate the anti-
atrophic effects that nerve activity has on muscle mass.
Denervation and/or disuse cause severe atrophy of skel-
etal muscle in both humans and rodents (Kandarian and
Jackman 2006). When PGC-1 levels are maintained
transgenically, denervation causes much less muscle-
mass loss and maintains muscle fiber volume (Sandri et
al. 2006).
The size and morphology of neuromuscular junctions
(NMJ) are key regulators of many facets of skeletal
muscle function. Genes encoding proteins involved in
NMJ formation are thought to be controlled, at least in
part, by the transcription factor GA-binding protein
(GABP, alternatively called nuclear respiratory factor 2,
NRF-2) (Kummer et al. 2006). Transcriptionally active
GABP is a heterotetramer of the DNA-binding sub-
unit GABPA and the transactivating subunit GABPB.
PGC-1 has been shown to increase the transcript levels
of GABPA and the transcriptional activity of GABP,
though this original work was done in the context of
mitochondrial gene expression (Mootha et al. 2004). Two
lines of evidence suggested that PGC-1 might be a
strong regulator of the NMJ program in a broad sense.
First, PGC-1 is known to activate mitochondrial bio-
genesis and muscle fiber-type switching (Lin et al.
2002b), both regulated physiologically by exercise and
motor-nerve activity, as is NMJ remodeling (Wilson and
Deschenes 2005). Secondly, PGC-1 has been shown to
increase GABP activity in transient transfections of the
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utrophin promoter in cultured muscle cells and in
muscle in vivo (Angus et al. 2005). Whether this is
through elevation of GABPA expression by PGC-1 or
via physical binding and coactivation was not demon-
strated. These data raise several key questions. First, is
PGC-1 a dominant regulator of the broad program of
NMJ formation in chronic gain and loss-of-function ex-
periments in vivo? Second, does PGC-1 actually bind to
and coactivate GABP on the NMJ genes? Finally, how
can the PGC-1/GABP complex be responsible for initi-
ating both the mitochondrial biogenesis and NMJ gene
programs in muscle fibers, when these programs are not
linked in synaptic and nonsynaptic nuclei in many
physiological circumstances (Ruegg 2005).
Duchenne muscular dystrophy (DMD) arises from a
frameshift mutation in the X-linked gene dystrophin and
leads to rapid degeneration of heart and skeletal muscle,
causing disability and death by adolescence or young
adulthood (Bogdanovich et al. 2004). No therapy de-
scribed to date can effectively slow or halt muscle de-
generation in these patients (Kapsa et al. 2003). Interest-
ingly, several gene programs that are linked to PGC-1
expression and function are dysregulated in DMD. These
include reduced capacity for mitochondrial oxidative
phosphorylation (Kuznetsov et al. 1998; Timmons et al.
2005) and radical oxygen species (ROS) detoxification
(Disatnik et al. 1998), abnormalities in calcium signaling
(Chakkalakal et al. 2006), and irregularities in NMJ mor-
phology in muscle damage and regeneration (Lyons and
Slater 1991).
In the current study, we show that PGC-1 stimulates
a broad and powerful program of NMJ-linked gene ex-
pression both in myotubes in culture and in vivo. More-
over, PGC-1 levels correlate with the number of
acetylcholine receptor (AChR) clusters in myotubes and
isolated single muscle fibers from transgenic animals.
We show unambiguously that moderately elevated lev-
els of PGC-1 in vivo ameliorate a murine model of
Duchenne muscular dystrophy (mdx) at the biochemical,
histological, and functional levels. These data support a
new therapeutic approach to the muscular dystrophies
through PGC-1.
Results
PGC-1 regulates NMJ gene transcription in vitro
and in vivo
To investigate whether PGC-1 can drive expression of a
broad NMJ gene program, we assessed the ability of
adenoviral-expressed PGC-1 to induce expression of
NMJ genes in C2C12 myotubes. After infection for 48 h
with adenoviral vectors encoding PGC-1, elevation of
mRNA-encoding AChR, AChEst, utrophin, ErbB2, lam-
inin 2 (laminin), rapsyn, and GABPA mRNA levels
were observed (Fig. 1A). The expression of these genes,
all of which are related to NMJ formation and function,
is increased in the range of three- to eightfold compared
with control cells infected with a GFP-expressing adeno-
virus.
The muscle-specific PGC-1 transgenic mouse repre-
sents a model of chronically elevated PGC-1 expression
(Lin et al. 2002b). Importantly, this mouse model has
moderate elevation of PGC-1 in most muscle beds to
the level of this protein observed in muscle beds rich in
oxidative fibers such as soleus. In gastrocnemius of these
Figure 1. PGC-1 regulates NMJ gene expression. (A) C2C12
myotubes were infected with adenoviral vectors encoding GFP
and PGC-1, respectively, on day 3 after differentiation. RNA
was harvested 48 h later and relative gene expression levels
were measured by real-time PCR. (*) p < 0.05 between GFP- and
PGC-1-infected cells. (B) Gastrocnemius muscle was isolated
from wild-type and PGC-1 muscle-specific transgenic animals
(MCK-PGC-1). After RNA isolation, relative gene expression
was analyzed by real-time PCR. (*) p < 0.05 between control and
transgenic animals. (C) Control and PGC-1 muscle-specific
knockout animals (PGC-1 MKO) were sacrificed, RNA was
isolated from gastrocnemius, and relative gene expression levels
were measured by real-time PCR. (*) p < 0.05 between control
and muscle-specific knockout animals. The bars depict average
gene expression normalized to 18S rRNA levels, with the error
bars representing standard deviations.
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animals, increased transcript levels of AChR, AChR,
AChR, AChEst, utrophin, ErbB2, rapsyn, and GABPA
are observed compared with wild-type skeletal muscle
(Fig. 1B).
PGC-1 whole-body knockout mice have a complex
phenotype characterized by massive lesions in the brain
and behavioral abnormalities (Lin et al. 2004; Leone et al.
2005; St-Pierre et al. 2006). In particular, these mice are
hyperactive and show Huntington-like behavior. Unfor-
tunately, many of the phenotypes resulting from abla-
tion of PGC-1 in peripheral tissues in these mice are
thus confounded by the hyperactivity. The validity of
tissue-specific knockout of PGC-1 has been proven in
liver-specific PGC-1 knockout mice, which have clear
and expected changes in liver function (Handschin et al.
2005). Accordingly, to selectively study the post-synap-
tic side of NMJs in skeletal muscle and to avoid the
confounding effects of genetic ablation of PGC-1 in the
central nervous system, we generated a skeletal muscle-
specific PGC-1 knockout animal by crossing mice with
a floxed PGC-1 allele with animals that transgenically
express cre recombinase under the control of the myo-
genin promoter and MEF2C enhancer. Similar to total
knockouts, mitochondrial gene expression and exercise
capacity is reduced in these mice (data not shown). Im-
portantly, muscle-specific knockout mice have reduced
expression of myosin heavy chains I and IIa and show no
signs of hyperactivity, in contrast to whole body PGC-1
knockout animals (data not shown). In gastrocnemius,
AChR, AChR, AChR, utrophin, ErbB2, Musk, and
GABPA expression levels are reduced between 30% and
70% in the muscle-specific knockout of PGC-1 as com-
pared with control animals (Fig. 1C). Thus, PGC-1 is
required for normal expression of the NMJ gene program.
Together, elevation and ablation of PGC-1 expression
in skeletal muscle in vivo both have marked effects on
the transcription of NMJ genes. NMJ genes are regulated
slightly differently in this experimental in vitro system
and in vivo. Importantly, the program of NMJ genes is
consistently regulated in C2C12 cells, MCK-PGC-1,
and MKO mice (seven of 10 genes studied in C2C12,
eight of 10 genes in MCK-PGC-1, and eight of 10 genes
in MKOs).
PGC-1 increases AChR clusters in myotubes
We next studied the effect of PGC-1 on AChR cluster-
ing in C2C12 myotubes induced by overnight treatment
with 10 ng/mL of a recombinant, C-terminal fragment of
rat agrin. C2C12 myoblasts and myotubes have very low
levels of endogenous PGC-1. Untreated, GFP-infected
myotubes show only sporadic clustering of AChR on the
cell membrane (Fig. 2A, top left panel). Agrin treatment
of GFP-infected myotubes greatly increases the number
of AChR clusters (Fig. 2A, top right panel). Surprisingly,
forced expression of PGC-1 using adenoviral vectors re-
sults in a marked increase in AChR clusters, even in the
absence of agrin (Fig. 2A, bottom left panel). Upon treat-
ment with agrin, a further increase in AChR clusters was
observed in PGC-1-infected C2C12 myotubes (Fig. 2A,
bottom right panel). In vehicle-treated myotubes, the
clusters appear more dispersed as compared with the
clusters on agrin-treated cells. This might be due to the
PGC-1-mediated increase in AChRs at the cell mem-
brane, which are able to bind -bungarotoxin (-BTX).
Adenoviral-encoded PGC-1 does not change endog-
enous agrin transcript levels in C2C12 cells (Supplemen-
Figure 2. AChR clustering induced by PGC-1. (A) C2C12
myotubes were infected with adenoviral GFP and PGC-1, re-
spectively, for 48 h. Sixteen hours before harvesting, the myo-
tubes were treated with vehicle (PBS) or 10 ng/mL recombinant
agrin. Subsequently, cells were fixed and incubated with rhoda-
mine-labeled -BTX, and AChR clusters were visualized by
fluorescence microscopy. (B,C) The average number of NMJ
counted in 20 fields per genotype was normalized to the number
of nuclei in these fields, and relative acetylcholine cluster num-
bers were expressed as percentage of control mice. (*) p < 0.05
between muscle fibers from MCK-PGC-1 and controls as well
as fibers from MKO and controls, respectively.
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tary Fig. S1). Importantly, these dispersed AChR clusters
are focused by treatment with exogenous agrin. These
results demonstrate that PGC-1 promotes an increase
of AChR clusters on the cell membrane (see Supplemen-
tary Fig. S2 for quantification).
To investigate whether AChR cluster numbers are af-
fected by the relative levels of PGC-1 in muscle fibers
of gain- and loss-of-function animals, we isolated single
muscle fibers from control, MCK-PGC-1 muscle-spe-
cific transgenic mice, and muscle-specific PGC-1
knockout animals. AChR clusters were stained with
fluorescent -BTX and their relative number normalized
by the muscle fiber area as assessed by the numbers of
nuclei stained with DAPI (4,6-diamidino-2-phenylin-
dole). Twenty different randomly chosen fields per ani-
mal were analyzed in blinded fashion and the average
reported. Single muscle fibers from MCK-PGC-1 had a
higher number of AChR clusters per muscle fiber area
than control animals (Fig. 2B). In contrast, fewer AChR
clusters were counted in PGC-1 muscle-specific knock-
out animals in comparison to control littermates (Fig.
2C). The increase in AChR clusters in the fibers of PGC-
1 muscle-specific transgenic mice and the decrease in
the fibers of muscle-specific PGC-1 knockout animals
were both significant, with an increase of 85% in MCK-
PGC-1 fibers and a decrease of 19% in MKO fibers
(Fig. 2B,C). Representative images and additional quan-
tification are shown in Supplementary Figure S3. Thus,
PGC-1 drives the formation of AChR clusters when
expressed ectopically in immortalized cell lines that are
differentiated into myotubes. Moreover, the number of
aneural AChR clusters in isolated single muscle fibers
from MCK-PGC-1 and MKO animals correlate with the
relative expression levels of PGC-1.
PGC-1 binding to and coactivation of GABP depends
on specific protein phosphorylation events
PGC-1 in skeletal muscle has been shown to induce
GABPA mRNA levels and increase GABP activity in the
context of transcriptional regulation of mitochondrial
genes, but direct binding and coactivation was not deter-
mined (Mootha et al. 2004). Similarly, PGC-1 and
GABP increase reporter gene expression driven by the
utrophin promoter construct, although again, direct
binding of PGC-1 to GABP could not be shown (Angus
et al. 2005). GABP represents a likely candidate tran-
scription factor recruiting PGC-1 to NMJ promoters,
but whether and how these events occur is unclear. In
reporter gene assays using promoter fragments from
AChR, AChR, and utrophin, PGC-1 stimulated
GABP-mediated transcription of all three promoters
(Fig. 3A). Transcriptional activity of GABP, PGC-1, and
the combination of these two proteins is completely de-
pendent on the integrity of the N-box present in all three
promoters (Fig. 3A). These results show that PGC-1 in-
duces transcription of these NMJ genes via the N-box,
the DNA-binding site for GABP. In skeletal muscle, sig-
naling cascades initiated by trophic factors such as agrin
or neuregulin-1 (NRG-1) result in phosphorylation of
GABP (Bezakova and Ruegg 2003; Sunesen and Chan-
geux 2003). Interestingly, mitogen-activated protein
kinase (MAPK) has been found to phosphorylate both
GABP (Flory et al. 1996) as well as PGC-1 (Puigserver et
al. 2001). These phosphorylation events are critical in
boosting the transcriptional activity of GABP (Sunesen
et al. 2003). We therefore mutated the known p38 MAPK
phosphorylation sites on GABPA (Thr 280) and GABPB1
(Ser 170 and Thr 180) (Fromm and Burden 2001) and used
these phosphorylation mutants along with the PGC-1
allele with mutated MAPK phosphorylation sites (PGC-
1 3A, Thr 262, Ser 265, and Thr 298) (Puigserver et al.
2001) in reporter gene assays with the AChR, AChR,
and utrophin promoters. Mutation of the three phos-
phorylation sites on PGC-1 resulted in complete abla-
tion of PGC-1-mediated coactivation of GABP on all
three promoters (Fig. 3B). Similarly, preventing the phos-
phorylation of GABPA and GABPB1 abolished transcrip-
tional induction of the AChR, AChR, and utrophin
promoters by GABP and PGC-1 (Fig. 3B). Using the
phosphorylation mutants for GABPA and GABPB1 indi-
vidually resulted in a partially reduced transcriptional
activity of the GABP/PGC-1 complex (Supplementary
Fig. S4). These data underline the previously reported
importance of the phosphorylation events on GABP
(Sunesen et al. 2003) and furthermore show that phos-
phorylation of PGC-1 is equally crucial for promoting
expression of these NMJ genes.
NRG-1 action requires phosphorylation of PGC-1
and GABP
NRG-1 promotes phosphorylation of GABP in skeletal
muscle and induces the expression of NMJ genes (Kum-
mer et al. 2006). In reporter gene assays using the
AChR, AChR, and utrophin promoters, NRG-1 dra-
matically increases the ability of GABP and PGC-1 to
promote reporter gene expression (Fig. 3C). Finally, the
NRG-1-mediated boost in activation of these three
promoters by PGC-1/GABP is markedly reduced when
using dominant-negative GABP. Dominant-negative
GABPA lacking the C-terminal dimerization domain
and dominant-negative GABPB1 lacking the C-terminal
transcriptional activation signal and the homodimeriza-
tion domain have been described (see Sunesen et al.
2003, and references therein). We used those in combi-
nation with the GABP and PGC-1 phosphorylation mu-
tants to test the ability of these mutants to block NRG-1
activity on the NMJ promoters. We found that func-
tional PGC-1 and GABP are essential for proper regu-
lation of reporter gene transcription (Fig. 3D). Induction
of endogenous NMJ genes by transfected PGC-1 in
C2C12 cells is significantly blunted by addition of ex-
pression vectors for dominant-negative GABP (Sup-
plementary Fig. S5). Together, these experiments show
that PGC-1 and GABP functionally interact and drive
the expression of several NMJ genes. Moreover, activa-
tion of the AChR, AChR, and utrophin promoters by
NRG-1 requires phosphorylation of both GABP and
PGC-1.
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To date, no direct protein interaction between GABP
and PGC-1 has been demonstrated (Scarpulla 2002;
Baar 2004; Angus et al. 2005; our unpublished observa-
tions). However, our results highlighting the importance
of the phosphorylation of both GABP and PGC-1 for
NMJ gene expression suggested that these post-transla-
tional modifications could be important for stabilizing
their physical interaction as well. Moreover, host cell
factor (HCF) was found to bind to both GABPB (Vogel
and Kristie 2000) and to PGC-1 (Lin et al. 2002a), and
Figure 3. PGC-1 and GABP activate NMJ gene promoters. (A) C2C12 myoblasts were transfected with wild-type and N-box mutated
promoter constructs, respectively, together with expression plasmids for PGC-1, GABPA, and GABPB1 (the combination of GABPA
and GABPB1 is referred to as GABP). The cells were subsequently differentiated for 2 d and harvested, and luciferase activity was
measured. (B) C2C12 myoblasts were transfected with NMJ promoter constructs together with expression plasmids for PGC-1,
GABP, PGC-1 3A, and GABPA as well as GABPB1 alleles (collectively called GABP P-mut) with mutated phosphorylation sites. The
cells were subsequently differentiated for 2 d and harvested, and luciferase activity was measured. (C) C2C12 myoblasts were
transfected with NMJ promoter constructs together with expression plasmids for PGC-1 and GABP. The cells were subsequently
differentiated for 2 d. Simultaneously, cells were treated with vehicle (PBS) 5 nM recombinant NRG-1. Cells were harvested and
luciferase activity was measured. (D) C2C12 myoblasts were transfected with NMJ promoter constructs together with expression
plasmids for PGC-1, GABP, PGC-1 3A, and GABPA as well as GABPB1 alleles (collectively called GABP P-mut) with mutated
phosphorylation sites. The cells were subsequently differentiated for 2 d. Simultaneously, cells were treated with vehicle (PBS) 5 nM
recombinant NRG-1. Cells were harvested and luciferase activity was measured. The bars depict average luciferase expression
normalized to -galactosidase activity, with the error bars representing standard deviations.
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thus, could potentially serve as a linker between GABP
and PGC-1. The importance of the phosphorylation and
binding of HCF in the formation of a GABP–PGC-1 com-
plex were tested in coimmunoprecipitation assays in
BOSC cells. Myc-tagged GABPA, myc-tagged GABPB1,
and Flag-tagged PGC-1 were cotransfected, cell extracts
were immunoprecipitated with anti-myc antibody, and
subsequently blotted with anti-myc and anti-Flag anti-
bodies. In this context, Flag-tagged PGC-1 was not as-
sociated with myc-tagged GABP (Fig. 4A, lane 2). Next,
phosphorylation of PGC-1, GABPA, and GABPB1 was
induced by cotransfection of constitutively active mito-
gen-activated protein kinase kinase kinase (MEKK*).
Transfection of MEKK* resulted in increased PGC-1
protein levels as published (Fig. 4A, lanes 3,5) (Puigserver
et al. 2001). No physical interaction between PGC-1
and GABP was observed with cotransfected MEKK* (Fig.
4A, lane 3). Similarly, addition of HCF expression plas-
mid yielded no coimmunoprecipitation of PGC-1 with
GABP (Fig. 4A, lane 4). However, cotransfection of both
constitutively active MEKK* and HCF strongly pro-
moted a physical interaction, as evidenced by detection
of Flag-PGC-1 after anti-myc immunoprecipitation
(Fig. 4A, lane 5).
Having established the importance of phosphorylation
and presence of HCF for physical interaction between
PGC-1 and GABP, we further tested whether phos-
phorylation of GABPA, GABPB1, or PGC-1 is impor-
tant for the interaction. Substitution of wild-type PGC-
1 with the PGC-1 3A allele completely abolished the
interaction between PGC-1 and GABP (Fig. 4B, lane 2
vs. lane 3). Similarly, mutation of the phosphorylation
Figure 4. Physical interaction between PGC-1 and GABP requires phosphorylation and HCF. (A) BOSC cells were transfected with
expression plasmids for Flag-tagged PGC-1, myc-tagged GABPA and GABPB1, constitutively active MEKK (MEKK*), and HCF as
indicated. Cells were harvested 48 h after transfection, 1 mg of total protein from the cell lysates was incubated with anti-myc beads,
and the bound proteins as well as input (10 µg protein) were blotted with anti-Flag and anti-myc antibodies. (B) BOSC cells were
transfected with expression plasmids for Flag-tagged PGC-1, myc-tagged GABPA and GABPB1, the phosphorylation-deficient alleles
Flag-PGC-1 3A, myc-GABPA P-mut, and myc-GABPB1 P-mut, respectively, constitutively active MEKK (MEKK*), and HCF as
indicated. Cells were harvested 48 h after transfection, 1 mg of total protein from the cell lysates was incubated with anti-myc beads,
and the bound proteins as well as input (10 µg protein) were blotted with anti-Flag and anti-myc antibodies. (C) C2C12 myotubes were
transfected with expression plasmids for Flag-tagged PGC-1, myc-tagged GABPA and GABPB1, constitutively active MEKK (MEKK*),
and HCF as indicated. The cells were differentiated for 2 d and simultaneously treated with 5 nM recombinant NRG-1. Cells were
harvested, 1 mg of total protein from the cell lysates was incubated with anti-myc beads, and the bound proteins as well as input (10
µg protein) were blotted with anti-Flag and anti-myc antibodies. (D) GABPA and GABPB1 bind as heterotetramers and upon phos-
phorylation of GABPB1 recruit phosphorylated PGC-1 and HCF. These phosphorylation events are induced by NRG-1 signaling or
constitutive MAPK activation.
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sites of GABPB1 resulted in greatly diminished coimmu-
noprecipitation of PGC-1 and GABP (Fig. 4B, lane 4). In
contrast, phosphorylation of GABPA is not important
for this interaction (Fig. 4B, lane 5). As predicted, co-
transfection of phosphorylation mutants for GABPA,
GABPB1, and PGC-1 did not result in any interaction
(Fig. 4B, lane 6). In all of these experiments, we used
constitutively active MEKK* to induce phosphorylation
of GABP and PGC-1. To see whether the interaction
between PGC-1 and GABP can be recapitulated in a
more physiological context, coimmunoprecipitation ex-
periments were performed in C2C12 myotubes treated
with NRG-1. Interestingly, NRG-1 promoted coimmu-
noprecipitation of PGC-1 with GABP even in the ab-
sence of exogenous HCF (Fig. 4C, lane 3 with NRG-1 vs.
lane 1 without NRG-1 treatment). However, addition of
HCF further stimulated the interaction (Fig. 4C, lane 4).
Our data demonstrate that PGC-1 and GABP are found
in a complex following phosphorylation of both PGC-1
and GABPB1, and that HCF is an important part of the
protein complex (Fig. 4D). Phosphorylation of the
GABPA subunit has been reported to be absolutely in-
dispensable for transcriptional activity and changes in
intranuclear mobility of the GABP complex (Sunesen et
al. 2003). In contrast, the function of the GABPB phos-
phorylation remained unclear (Sunesen et al. 2003). Our
findings suggest that GABPB1 phosphorylation is needed
for the recruitment of PGC-1, perhaps via the interac-
tion with HCF that exclusively binds to GABPB and not
GABPA (Vogel and Kristie 2000). The phosphorylation of
PGC-1 and GABP could furthermore control the speci-
ficity of the coactivation and direct the protein complex
to NMJ gene promoters. Thus, in primary myotubes de-
rived from wild-type animals, NRG-1 significantly in-
duced expression of AChR, AChR, AChEst, utrophin,
and Musk (Fig. 5A). In marked contrast, this induction
was completely lost in PGC-1 knockout myotubes. In
contrast to NMJ genes, none of the PGC-1 target genes
involved in metabolic pathways is regulated by NRG-1
in wild-type and PGC-1 knockout primary myotubes,
respectively (Fig. 5B). These genes have previously been
shown to be under transcriptional control of GABP and
ERR coactivated by PGC-1 (Mootha et al. 2004). Fi-
nally, the phosphorylation-deficient PGC-1 3A protein
has no transcriptional activity on NMJ promoters, and
this protein is unable to interact with GABP in this con-
text (Fig. 5C). Surprisingly, PGC-1 3A is as efficient in
increasing GABP activity on the ERR promoter as wild-
type PGC-1 (Fig. 5C). Wild-type PGC-1 and PGC-1
3A both coactivate ERR on the ERR promoter to the
same extent (Fig. 5D). In addition, wild-type PGC-1 and
the PGC-1 3A protein were also equally potent in co-
activating the nuclear respiratory factor 1 in reporter
gene assays (Supplementary Fig. S6). These results
clearly show that increase of mitochondrial genes by co-
activation of GABP by PGC-1 is different from the
induction of NMJ genes, in that it requires phosphoryla-
tion of PGC-1 and GABP. Moreover, phosphoryla-
tion stimulated by NRG-1 only elevates NMJ genes,
but not mitochondrial or other PGC-1 target genes,
in skeletal muscle cells. Thus, NRG-1 directs modifica-
tions of GABP and PGC-1 and induces a very specific
subset of GABP/PGC-1 target genes in skeletal muscle
fibers.
PGC-1 ameliorates muscular dystrophy in sedentary
DMD (mdx) mice
Many genes controlled by PGC-1 are dysregulated in
DMD (see Discussion section for an overview). We there-
fore examined the effect of transgenic expression of
PGC-1 on the disease phenotype of mdx mice by inter-
breeding with MCK-PGC-1 muscle-specific transgenic
animals. The main pathology in mdx mice is detected at
the age of 4–6 wk. We thus analyzed our animals at 5 wk
of age. Introducing the PGC-1 transgene into the mdx
background reduced serum creatine kinase levels by
∼55% (Fig. 6A). As compared with control and MCK-
PGC-1 transgenic mice, haematoxylin and eosin (H&E)
staining of cross-sections of mdx gastrocnemius muscles
show a large proportion of muscle fibers with centrally
located nuclei (Fig. 6B). Muscle fibers with centrally lo-
cated nuclei are a hallmark of regenerating muscle and
their relative number is proportional to muscle damage
in mdx mice (e.g., for review, see Briguet et al. 2004). In
MCK-PGC-1/mdx mice, the relative numbers of
muscle fibers with centrally located nuclei are reduced
by 44% as compared with mdx animals (Fig. 6B; Supple-
mentary Fig. S7). Intraperitoneal injection of Evans blue
is commonly used to assess skeletal muscle fiber lesions,
since this dye will only penetrate damaged fibers. As
expected, no damaged fibers were found in gastrocne-
mius of control or MCK-PGC-1 transgenic mice (Fig.
6C). A substantial proportion of muscle fibers in mdx
mice is damaged, as indicated by penetration of Evans
blue (Fig. 6C). In contrast, expression of the PGC-1
transgene in skeletal muscle of mdx mice reduces the
fraction of damaged muscles by ∼55% (Fig. 6C; Supple-
mentary Fig. S6). These results clearly demonstrate
that elevation of PGC-1 levels in skeletal muscle has
a beneficial effect on the muscular dystrophy in mdx
mice through a reduction in muscle fiber damage. It is
conceivable that this improvement is at least in part me-
diated by increased utrophin levels in MCK-PGC-1/
mdx mice compared with mdx animals (Supplementary
Fig. S8).
PGC-1 improves muscular dystrophy in physically
challenged mdx mice
In contrast to human DMD patients, mdx mice have a
relatively mild muscular dystrophy that is most notice-
able at the age of 4–6 wk and is later offset by compen-
satory up-regulation of utrophin and massive muscle re-
generation (Bulfield et al. 1984). Dystrophin provides
mechanical reinforcement to the sarcolemma, and its
absence increases the susceptibility of muscle fibers to
contractile stress. However, mdx mice challenged with
eccentric physical exercise constitute a more reliable
Handschin et al.
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model of the human disease than sedentary mdx animals
(Brussee et al. 1997). Thus, wild-type, MCK-PGC-1,
mdx, and MCK-PGC-1/mdx were run on a treadmill for
1 h at 15° downhill. Subsequently, this exercise protocol
was repeated 24 h after the first run. Importantly, this
exercise protocol is not exhaustive for wild-type ani-
mals. Accordingly, wild-type and MCK-PGC-1 animals
had no problem running 1 h on two consecutive days
(Fig. 7A). In contrast, mdx mice barely make it through
50% of each run (Fig. 7A). MCK-PGC-1/mdx animals
perform almost as well as control mice in the first run;
they showed a decreased performance in the second run,
though their performance in the second run is still sig-
nificantly better than that of mdx mice in the first or the
second run (Fig. 7A).
Two hours after the first run, serum creatine kinase
activity was determined, which is a reflection of the
muscle damage induced by the eccentric exercise. Serum
creatine kinase levels of mdx animals were about seven-
fold higher that those in sedentary mdx mice (Fig. 7B vs.
Fig. 6B). The MCK-PGC-1/mdx mice had a 50% reduc-
tion in creatine kinase levels after exercise, similar to
the reduction observed in sedentary animals (Fig. 7B).
Histological analysis of quadriceps muscles from mice
sacrificed after the second run revealed a lower number
of necrotic lesions in the MCK-PGC-1/mdx mice as
compared with mdx animals (Fig. 7C). Moreover, a
greater number of large and noncentrally nucleated fi-
bers are found in MCK-PGC-1/mdx than mdx mice
(Fig. 7C; Supplementary Fig. S7). Similarly, fiber damage
Figure 5. Specificity of NRG-1-induced NMJ gene expression via PGC-1. (A,B) Primary muscle cells were isolated from control and
PGC-1 knockout animals. After differentiation into myotubes, cells were treated with vehicle (PBS) or 5 nM recombinant NRG-1 for
48 h. RNA was isolated from harvested cells and relative gene expression levels of NMJ genes (A) and other PGC-1 target genes (B)
were determined by real-time PCR. (*) p < 0.05 between vehicle and NRG-1 treated cells. The bars depict average gene expression
normalized to 18S rRNA levels, with the error bars representing standard deviations. (C,D) C2C12 myoblasts were transfected with
a reporter plasmid containing the ERR promoter and expression plasmids for PGC-1, GABPA and GABPB1 (called GABP), ERR, and
the phosphorylation-deficient PGC-1 3A. The cells were subsequently differentiated for 2 d and harvested, and luciferase activity
controlled by PGC-1 and GABP (C) and PGC-1 and ERR (D) was measured. The bars depict average luciferase expression normal-
ized to -galactosidase activity, with the error bars representing standard deviations.
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as determined by Evans blue uptake is lower in MCK-
PGC-1/mdx diaphragms versus mdx diaphragms (Fig.
7D; Supplementary Fig. S7). Thus, the moderately el-
evated PGC-1 in skeletal muscle results in an improve-
ment in fiber damage, fiber necrosis, and a decrease in
serum creatine kinase levels in a mouse model of DMD
to an extent that results in vastly improved exercise tol-
erance. Together, these effects of ectopic expression of
PGC-1 show a clear and substantial improvement in
the structure and function of skeletal muscle in this dis-
ease model.
Discussion
The size and morphology of NMJs evolves in develop-
ment and changes according to the relative degree of
Figure 6. PGC-1 ameliorates muscle dystrophy in
sedentary mdx mice. (A) Five-week-old control, PGC-
1 muscle-specific transgenic (MCK-PGC-1), mdx,
and PGC-1 muscle-specific transgenic animals in the
mdx background (MCK-PGC-1/mdx) were sacrificed
and serum creatine kinase activity was determined.
The bars depict the average serum creatine kinase lev-
els, and error bars represent standard deviations. (B)
H&E-stained histology of gastrocnemius from control,
PGC-1 muscle-specific transgenic (MCK-PGC-1),
mdx, and PGC-1 muscle-specific transgenic animals
in the mdx background (MCK-PGC-1/mdx). (C) Five-
week-old control, PGC-1 muscle-specific transgenic
(MCK-PGC-1), mdx, and PGC-1 muscle-specific
transgenic animals in the mdx background (MCK-PGC-
1/mdx) were injected i.p. with 1% v/w Evans blue so-
lution and sacrificed 16 h later. Dye incorporation into
muscle fibers was visualized by fluorescence micros-
copy.
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physical activity and the fiber-type distribution (Wilson
and Deschenes 2005; Hughes et al. 2006). NMJ formation
and plasticity are controlled by the trophic factors agrin
and NRG-1 released from the motor neuron (Kummer et
Figure 7. PGC-1 improves muscle function in exercised mdx mice. (A) Twelve-week-old control, PGC-1 muscle-specific transgenic
(MCK-PGC-1), mdx, and PGC-1 muscle-specific transgenic animals in the mdx background (MCK-PGC-1/mdx) were run for 1 h on a
treadmill at a 15° downhill angle (first run). This exercise protocol was repeated after a resting period of 24 h (second run). The bars depict
average running times, with the error bars representing standard deviations. (B) Two hours after the first run, blood was drawn from the
mice and serum creatine kinase activity was determined. The bars depict average serum creatine kinase levels, with the error bars
representing standard deviations. (C) Mice were sacked after the second run and gastrocnemius sections were stained with H&E. (D) Before
sacking, Evans blue was injected i.p. and histological sections from diaphragms were analyzed by fluorescence microscopy.
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al. 2006). Agrin stimulates clustering of AChRs at the
site of the NMJ and promotes transcription of NMJ-spe-
cific genes. NRG-1 is sufficient to induce transcript lev-
els of many NMJ genes, although recent reports showed
that NRG-1 signaling is not required for NMJ formation
in vivo (Escher et al. 2005; Jaworski and Burden 2006).
Importantly, agrin and NRG-1 signaling both converge
on the transcription factor GABP (Briguet and Ruegg
2000). The two GABP subunits, GABPA and GABPB, are
subsequently phosphorylated and bind to N-box ele-
ments in the promoters of NMJ genes. We now show
that PGC-1 is a powerful transcriptional regulator of
the NMJ gene program, at least in part by a bona fide
coactivation of GABP. Moreover, we demonstrate that
the relative levels of PGC-1 are important for the for-
mation of AChR clusters in isolated muscle fibers. The
changes in NMJ gene expression and in relative AChR
cluster numbers induced by PGC-1 in the basal (non-
exercised) state are moderate. Moreover, NMJ formation
per se can clearly happen in vivo in the absence of PGC-
1. As observed for PGC-1 in skeletal muscle in gen-
eral, this coactivator does not regulate basal functions as
much as adaptive changes in response to exercise and
other physiological alterations. The rapid changes in
PGC-1 levels upon physical exercise and inactivity
(e.g., Pilegaard et al. 2003; Russell et al. 2003) imply that
PGC-1 is probably very important for adaptive changes
in the NMJ gene program in certain contexts. In addi-
tion, as shown here, the changes induced by PGC-1 are
striking in mice with an mdx background.
Induction of GABPA transcript levels and increase of
GABP activity by PGC-1 in the context of mitochon-
drial genes has previously been shown (Mootha et al.
2004). However, we here show for the first time that
PGC-1 physically interacts with and coactivates GABP.
Importantly, our results give an indication as to how
PGC-1 and GABP specifically regulate NMJ gene ex-
pression in synaptic nuclei. PGC-1 is required for the
effects of NRG-1 that promotes phosphorylation of
GABP to increase transcription of NMJ genes. Further-
more, we found that the interaction between PGC-1
and GABP is highly dependent on the phosphorylation
state of PGC-1 and GABPB1, the transactivating sub-
unit of GABP. Phosphorylation of GABPA has previously
been reported to change the mobility of the GABP com-
plex in the nucleus (Sunesen et al. 2003). The signifi-
cance of the GABPB1 phosphorylations has not been
clear to date (Sunesen et al. 2003). Here, we propose that
these post-translational modifications on GABPB1 con-
trol the recruitment of PGC-1 to GABP. In addition,
PGC-1 requires the presence of HCF in the PGC-1–
GABP protein complex. Additional members of the tran-
scriptional PGC-1/HCF/GABP complex and the exact
domains mediating these interactions will be identified
in future studies. In all of the interactions studied to
date, PGC-1 directly binds to the transcription factor it
coactivates. Why coactivation of GABP by PGC-1 re-
quires these additional steps is not clear. However, it is
plausible that the requirement for phosphorylations and
the presence of HCF may control the interaction be-
tween PGC-1 and GABP specifically in synaptic nuclei
where NMJ genes are expressed. Unfortunately, due to
the lack of suitable tools, we were not able to study the
significance of the phosphorylation of endogenous PGC-
1 and GABP. Obviously, characterizing the post-trans-
lational modifications of the endogenous proteins in
skeletal muscle in vivo will contribute to our under-
standing of the signaling cascades involved in NMJ re-
modeling in the future.
PGC-1 muscle-specific transgenic mice in an mdx
background have lower creatine kinase levels, reduced
necrotic lesions, decreased fiber damage, and increased
muscle function. NRG-1 treatment, which improves the
function of mdx mice (Krag et al. 2004), has been pro-
posed to work through up-regulation of utrophin, since
NRG-1 has no beneficial effect in dystrophin/utrophin
double-knockout animals (Krag et al. 2004) and trans-
genic expression of utrophin ameliorates muscle damage
in mdx animals (Tinsley et al. 1998). One obvious link
between the PGC-1-mediated changes in NMJ gene ex-
pression and amelioration of muscle dystrophy in mdx
mice is the induction of utrophin mRNA and protein
(Fig. 1; Supplementary Fig. S9). Elevation of utrophin has
been proposed to constitute a therapeutic approach to
DMD (Miura and Jasmin 2006). However, although the
outcome of crossing muscle-specific PGC-1 transgenic
animals into a dystrophin/utrophin double-knockout
background is unknown, there is strong evidence sug-
gesting that PGC-1 has beneficial effects on DMD that
go well beyond simple increase of utrophin expression.
First, PGC-1 has an anti-atrophic effect on muscle fi-
bers in sciatic nerve denervation (Sandri et al. 2006). The
exact mechanism of this effect is unknown, but it is
clear that PGC-1 inhibits the function of the proatro-
phic transcription factor FoxO3 and blunts induction of
the atrogenes atrogin-1, MuRF-1, and cathepsin-L (Sandri
et al. 2006). Recent data have shown that dystrophin
disruption as observed in DMD results in down-regula-
tion of Akt signaling, subsequent activation of FoxO3,
and elevation of the atrogenes (Acharyya et al. 2005).
Second, PGC-1 is a potent regulator of mitochondrial
biogenesis and oxidative metabolism in skeletal muscle
(Wu et al. 1999; Lin et al. 2002b). The skeletal muscles of
mdx mice have impaired oxidative phosphorylation and
mitochondrial function (Kuznetsov et al. 1998; Tim-
mons et al. 2005). Moreover, in skeletal muscle of DMD
patients, a general metabolic crisis is precipitated by a
large-scale down-regulation of nuclear-encoded mito-
chondrial genes (Chen et al. 2000). Third, PGC-1 is a
direct target of calcium/calmodulin signaling in skeletal
muscle (Wu et al. 2002; Handschin et al. 2003). Disrup-
tion of calcium/calmodulin signaling in mdx mice exac-
erbates the dystrophic phenotype (Chakkalakal et al.
2006). Fourth, mdx show abnormalities in NMJ mor-
phology in fiber damage and regeneration (Lyons and
Slater 1991) that might be prevented by the PGC-1-
mediated induction of NMJ genes. Finally, reactive oxy-
gen species (ROS) may be causally linked to the muscle
damage in DMD (Disatnik et al. 1998). The normal cel-
lular response to ROS challenge relies on PGC-1, which
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is a potent driver of the gene program for ROS defense
(St-Pierre et al. 2006).
In summary, PGC-1 most likely improves muscle
dystrophy by multiple molecular pathways. Thus, an in-
crease in PGC-1 levels or PGC-1 activity and recruit-
ment to specific transcription factors such as GABP rep-
resent a promising and novel strategy for the treatment
of DMD, the related Becker muscular dystrophy, and
other neuromuscular diseases.
Materials and methods
Plasmids and reagents
Promoter constructs for AChR (770 base pair [bp]), AChR (210
bp), and utrophin (1.2 kb) were amplified by PCR and subcloned
into the pGL3 basic luciferase reporter gene plasmid (Promega),
similar to published constructs (Koike et al. 1995; Duclert et al.
1996; Gramolini et al. 1998). Mutations of the N-box DNA el-
ements in these promoters were obtained by PCR-mediated
site-directed mutagenesis. Phosphorylation mutants of GABPA
(Thr 280) and GABPB1 (Ser 170 and Thr 180) were obtained by
site-directed mutagenesis replacing the threonines and serines
with alanines. Myc tags were C-terminally attached to GABPA
and N-terminally attached to GABPB1 by PCR. Dominant-
negative GABPA and GABPB1 alleles lacking amino acids 400–
454 and 330–383, respectively, were obtained by PCR. Consti-
tutively active MEKK3 was used to induce phosphorylation of
PGC-1 and GABP. All constructs were verified by sequencing.
Recombinant rat C-terminal agrin and recombinant human
NRG-1 extracellular domain were purchased from R&D Sys-
tems. Tetramethylrhodamine-labeled -BTX was obtained from
Invitrogen.
Mdx animals
C57BL/10ScSn-Dmdmdx/J mice (mdx mice) (Bulfield et al. 1984)
were purchased from Jackson Laboratories. These mice were
crossed with the previously described muscle-specific PGC-1
transgenic animals (Lin et al. 2002b). To control variations of
different genetic backgrounds (MCK-PGC-1: C57Bl/6J; mdx:
C57Bl/10ScSnJ), only littermates from the breeding were used
in sufficient number per experimental group. Sedentary mice
were analyzed at the age of 5 wk, eight animals per group. For
the exercise experiment, mice at the age of 12 wk were used, six
animals per group.
PGC-1 muscle-specific knockout animals
The generation of mice with a floxed PGC-1 allele has been
described (Lin et al. 2004). To obtain muscle-specific knockout
animals, mice with a loxed PGC-1 allele were crossed with
animals transgenically expressing cre recombinase under the
control of the myogenin promoter and MEF2C enhancer (a gen-
erous gift from Rhonda Bassel-Duby and Eric N. Olson, Univer-
sity of Texas Southwestern Medical Center, Dallas, TX; Li et al.
2005). However, male mice with the floxed PGC-1 allele are
infertile because of the presence of the neomycin cassette.
Thus, muscle-specific knockout animals could only be obtained
in mice with one floxed and one knockout allele of PGC-1
(lox/−, myogenin-cre). As control mice, we used a mixed popu-
lation of different mice heterozygous for PGC-1 (lox/−; +/−;
+/−, myogenin-cre). A detailed description of the muscle-spe-
cific knockout animals will be published elsewhere. Muscle-
specific knockout animals and MCK-PGC-1 animals were sac-
rificed at the age of 6 wk to analyze gene expression; six animals
per genotype were used.
Cell culture
C2C12 cells were cultured in DMEM (Invitrogen) with 10% FBS
(GIBCO) and differentiated in DMEM with 2% horse serum
(GIBCO) for 3 d. Differentiated myotubes were infected with
adenoviral vectors and cells were harvested after 48 h. Primary
muscle cells were isolated from whole hind-leg muscles by en-
zymatic digestion with collagenase/dispase (Roche) and serial
plating on collagen-coated culture dishes (BD Biosciences).
These cells were cultured in Ham’s F-10 medium (Invitrogen)
supplemented with 20% FBS (Hyclone) and 2.5 ng/mL basic
fibroblast growth factor (Invitrogen). Differentiation was in-
duced by addition of DMEM with 5% horse serum.
Single muscle fiber culture and NMJ quantification
Single muscle fibers were prepared as described (Rosenblatt et
al. 1995). Briefly, extensor digitorum longus (EDL) muscle was
removed from 6-wk-old animals by cutting the tendons. The
muscle was placed in 0.2% collagenase solution and incubated
for 60 min at 35°C. Single muscle fibers were liberated from the
EDL by shearing using heat-polished Pasteur pipettes in DMEM
supplemented with 10% horse serum (GIBCO). The fibers were
washed in PBS and fixed in 1.5% paraformaldehyde for 10 min.
Subsequently, the fibers were stained with -BTX in PBS for 30
min, washed twice in PBS with 20 mM glycine, and transferred
to a glass slide. The fibers were embedded in SlowFade Gold
anti-fade reagent with DAPI (Invitrogen) and analyzed by fluo-
rescent microscopy. At a 60× magnification, 20 fields contain-
ing muscle fibers were randomly chosen per animal, and the
number of NMJs as well as the number of nuclei were counted.
For the histogram depicting the relative number of AChR clus-
ters per muscle fiber, 50 muscle fibers per genotype were ana-
lyzed and AChR were counted.
Transient transfections
C2C12 myoblasts were transfected with Lipofectamine 2000 at
80% confluency and subsequently differentiated for 2 d. In some
experiments, cells were treated for 2 d with vehicle or 5 nM
NRG-1. Then, cells were harvested, and luciferase activity was
measured and normalized to -galactosidase levels.
Coimmunoprecipitation
BOSC cells were transfected by calcium phosphate precipita-
tion (Promega). Two days after transfection, cells were har-
vested, proteins were isolated, and 1 mg of protein extract was
used for immunoprecipitation with anti-myc beads (Santa Cruz
Biotechnology). Proteins were subsequently eluted from the
beads and analyzed by Western blotting using anti-Flag (Sigma)
and anti-myc (Santa Cruz Biotechnology) antibodies along with
10 µg of input. C2C12 cells were transfected by calcium phos-
phate precipitation at 80% confluency, differentiated for 2 d,
and simultaneously treated with vehicle or 5 nM NRG-1. Then,
cells were harvested and processed as described above.
AChR clustering in vitro
C2C12 cells were differentiated for 3 d and infected with ad-
enoviral vectors encoding GFP and PGC-1, respectively. After
1.5 d, cells were treated with vehicle or 10 ng/mL agrin for 16 h.
Cells were fixed in 3% formaldehyde, incubated with -BTX to
stain NMJs, and analyzed by fluorescence microscopy.
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Histological analysis, Evans blue injection
Tissues were dissected, embedded in OCT compound (VWR),
dehydrated, embedded in paraffin, and sectioned. The sections
were subsequently stained with H&E. Evans blue dye (1% so-
lution) was i.p.-injected at a concentration of 1% volume per
gram of body weight. After 16 h, mice were sacrificed and skel-
etal-muscle frozen histological sections were prepared. Evans
blue incorporation was analyzed by fluorescence microscopy.
Evans blue-penetrated muscle fibers and fibers with centrally
located nuclei were counted in 20 randomly chosen sections in
blinded fashion and were normalized by the total number of
muscle fibers per field.
RNA isolation and real-time PCR analysis
Total RNA from cells or tissues was prepared using the Trizol
reagent (GIBCO). Before reverse transcription, 1 µg of total RNA
was treated with DNase I (Roche) and then treated with MMLV
reverse transcriptase (Invitrogen). This cDNA was subsequently
analyzed by semiquantitative real-time PCR using the Ct
method on an Applied Biosystems Real-Time PCR System
7300. Relative gene expression levels were normalized to 18S
rRNA expression.
Serum creatine kinase assay
Mouse blood was collected and serum-isolated using heparin-
coated collection tubes (BD Biosciences). Serum creatine kinase
activity was then determined with the Creatine Kinase-SL As-
say Kit according to the manufacturer’s protocol (Diagnostic
Chemicals Limited).
Treadmill exercise
Animals ran on a treadmill tilted 15° downhill until exhaustion
or for maximal 60 min. The running protocol consisted of 5 min
at 10 m/min, 5 min at 15 m/min, 5 min at 20 m/min, and 45
min at 25 m/min. The run was repeated 24 h after the first run.
Western blotting
Protein extract from gastrocnemius (100 µg) was run on a 6%
polyacrylamide gel, transferred to PVDF membrane, and blotted
for utrophin using an anti-utrophin antibody (Santa Cruz Bio-
tecnology).
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